X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2023/01/19/2591732/0/en/SAB-Biotherapeutics-CEO-Eddie-Sullivan-PhD-to-Present-Next-Generation-Biologics-in-Immunology-at-BIO-CEO-Investor-Conference.html
https://www.globenewswire.com/news-release/2023/01/18/2590857/0/en/SAB-Biotherapeutics-Receives-an-Additional-8-2-Million-in-Closeout-of-DoD-Contract.html
https://www.globenewswire.com/news-release/2023/01/10/2586085/0/en/SAB-Biotherapeutics-Successfully-Concludes-IND-Enabling-GLP-Toxicology-Study-for-SAB-142-a-Novel-Immunotherapeutic-for-Type-1-Diabetes.html
https://www.globenewswire.com//news-release/2023/01/05/2583622/0/en/SAB-Biotherapeutics-Novel-DiversitAb-Platform-Proven-to-Develop-Anti-idiotype-Antibodies-to-Help-Treat-Autoimmune-Diseases.html
https://www.globenewswire.com/news-release/2022/12/15/2574592/0/en/SAB-Biotherapeutics-CMO-Selected-to-Present-at-the-January-2023-Biotech-Showcase-in-San-Francisco.html
https://www.globenewswire.com//news-release/2022/12/07/2569776/0/en/SAB-Biotherapeutics-Announces-7-9-Million-Private-Placement-of-Common-Stock.html
https://www.globenewswire.com/news-release/2022/11/21/2559862/0/en/SAB-Biotherapeutics-Initiates-IND-Enabling-GLP-Toxicology-Study-for-SAB-142-Novel-Immunotherapeutic-for-Type-1-Diabetes.html
https://www.globenewswire.com/news-release/2022/11/15/2556190/0/en/SAB-Biotherapeutics-Provides-Company-Update-for-Q3-2022-Financial-Results.html
https://www.globenewswire.com/news-release/2022/11/08/2550953/0/en/SAB-Biotherapeutics-Presents-Novel-Biologic-Therapeutics-for-Infectious-Diseases-at-U-S-Pharma-Partnering-Summit-2022.html
https://www.globenewswire.com/news-release/2022/11/03/2547748/0/en/SAB-Biotherapeutics-Presents-Overview-of-DiversitAb-Platform-and-Data-Showing-Benefits-of-Fully-Human-Polyclonal-Antibodies-Derived-from-Cows-vs-Human-Derived-Plasma-at-2022-Plasma.html
Market Place
Share 
